dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our latest study explores patient confidence in interpreting ketone test results, DKA risk perceptions, and real-world testing behaviors in adults with type 1 Diabetes.
Our latest work examines the real-world psychosocial impact of Automated Insulin Delivery (AID) systems, analyzing user experiences, quality of life, and daily diabetes burden.
Our AI instantly delivers powerful, actionable diabetes insights from one of the world’s richest diabetes datasets.
dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
dQ&A Presented Three Abstracts at EASD 2023 | dQ&A
New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.
We partnered with LMC to connect real-world patient experience insights with validated clinical data for patients across the diabetes spectrum.
A dQ&A-CeQur study in Clinical Diabetes finds 2 months on the CeQur Simplicity insulin patch boosts patient satisfaction, cuts burden, and lifts well-being.
.png)
